Qiagen to acquire Nextal Biotechnology

Qiagen has agreed to buy Canada's Nextal Biotechnology for up to $14.2 million, with $9.7 million in cash and the rest paid out according to predetermined milestones. Nextal has developed products that "simplify the process of sample preparation of proteins for subsequent crystallographic analysis."

- read this press release for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.